Summary
Global Markets Direct’s, ‘Alcohol Addiction - Pipeline Review, H2 2016’, provides an overview of the Alcohol Addiction pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Alcohol Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Alcohol Addiction
- The report reviews pipeline therapeutics for Alcohol Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Alcohol Addiction therapeutics and enlists all their major and minor projects
- The report assesses Alcohol Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Alcohol Addiction
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Alcohol Addiction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alcohol Addiction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AbbVie Inc.
Addex Therapeutics Ltd
Adial Pharmaceuticals, LLC
Astraea Therapeutics, LLC
AstraZeneca Plc
Bionex Pharmaceuticals LLC
Bioprojet SCR
Cerecor Inc.
Curemark, LLC
Eli Lilly and Company
Ethypharm S.A.
Euthymics Bioscience, Inc.
H. Lund
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Alcohol Addiction Overview 10
Therapeutics Development 11
Pipeline Products for Alcohol Addiction - Overview 11
Pipeline Products for Alcohol Addiction - Comparative Analysis 12
Alcohol Addiction - Therapeutics under Development by Companies 13
Alcohol Addiction - Therapeutics under Investigation by Universities/Institutes 15
Alcohol Addiction - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Alcohol Addiction - Products under Development by Companies 19
Alcohol Addiction - Products under Investigation by Universities/Institutes 21
Alcohol Addiction - Companies Involved in Therapeutics Development 22
AbbVie Inc. 22
Addex Therapeutics Ltd 23
Adial Pharmaceuticals, LLC 24
Astraea Therapeutics, LLC 25
AstraZeneca Plc 26
Bionex Pharmaceuticals LLC 27
Bioprojet SCR 28
Cerecor Inc. 29
Curemark, LLC 30
Eli Lilly and Company 31
Ethypharm S.A. 32
Euthymics Bioscience, Inc. 33
H. Lundbeck A/S 34
Heptares Therapeutics Limited 35
Indivior Plc 36
Johnson & Johnson 37
Kinnov Therapeutics SAS 38
Kyorin Pharmaceutical Co., Ltd. 39
Lohocla Research Corporation 40
Omeros Corporation 41
Pfizer Inc. 42
SK Biopharmaceuticals Co., Ltd. 43
Tonix Pharmaceuticals Holding Corp. 44
VM Discovery, Inc. 45
XenoPort, Inc. 46
Zynerba Pharmaceuticals, Inc. 47
Alcohol Addiction - Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Combination Products 49
Assessment by Target 50
Assessment by Mechanism of Action 53
Assessment by Route of Administration 56
Assessment by Molecule Type 58
Drug Profiles 60
(cyproheptadine hydrochloride + prazosin hydrochloride) - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
(disulfiram + selegiline) - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
A-705253 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
ABT-436 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
ADX-71441 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
amitifadine - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
arbaclofen placarbil - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
AT-1001 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
baclofen - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
carisbamate - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
CERC-501 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
CM-1212 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
gabapentin enacarbil ER - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
GET-73 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
ibudilast - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
JDTic - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
JNJ-5234801 - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
nalmefene - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
naltrexone hydrochloride - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
naltrexone hydrochloride - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
odelepran hydrochloride - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
OMS-527 - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
ondansetron hydrochloride - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
PF-05190457 - Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
pitolisant - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
saracatinib difumarate - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
SKL-10406 - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
Small Molecule for Alcohol Addiction - Drug Profile 113
Product Description 113
Mechanism Of Action 113
R&D Progress 113
Small Molecule to Agonize Oxytocin Receptor for Alcohol Addiction - Drug Profile 114
Product Description 114
Mechanism Of Action 114
R&D Progress 114
Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile 115
Product Description 115
Mechanism Of Action 115
R&D Progress 115
Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile 116
Product Description 116
Mechanism Of Action 116
R&D Progress 116
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile 118
Product Description 118
Mechanism Of Action 118
R&D Progress 118
Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile 119
Product Description 119
Mechanism Of Action 119
R&D Progress 119
Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety - Drug Profile 120
Product Description 120
Mechanism Of Action 120
R&D Progress 120
VMD-2202 - Drug Profile 121
Product Description 121
Mechanism Of Action 121
R&D Progress 121
Alcohol Addiction - Dormant Projects 122
Alcohol Addiction - Discontinued Products 125
Alcohol Addiction - Product Development Milestones 126
Featured News & Press Releases 126
Jun 29, 2016: MediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana 126
May 25, 2016: MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana 126
Dec 11, 2015: Publication Reports Human Brain Penetration and Target Engagement of Cerecor’s Oral Kappa Opioid Receptor Antagonist, CERC-501 127
Dec 09, 2015: MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting 128
Oct 13, 2015: Addex’ ADX71441 Demonstrates Robust Efficacy in Multiple Preclinical Models of Alcohol Use Disorder 128
Oct 01, 2015: XenoPort Announces Plan to Focus on its Growing HORIZANT Business and Names Vincent J. Angotti Chief Executive Officer and Director 129
Jun 30, 2015: MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 in Alcohol Dependence 130
Jun 25, 2015: XenoPort Announces Initiation by NIAAA of Clinical Trial of HORIZANT in Patients with Alcohol Use Disorder 131
Jun 24, 2015: MediciNova Announces Presentation of Interim Data from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence at the 38th Annual RSA (Research Society on Alcoholism) Scientific Meeting 131
Jan 11, 2015: XenoPort Provides Highlights of HORIZANT Prescription Trends and Update on Development for Alcohol Use Disorder 132
Jan 07, 2015: Addex and NIAAA Enter Collaboration to Evaluate ADX71441 in Alcohol Use Disorder 133
Nov 26, 2014: Biotie: UK's Nice Issues Positive Final Guidance For Selincro 134
Nov 26, 2014: Drug recommended to help cut drink dependence 134
Sep 09, 2014: XenoPort and the NIAAA Announce Clinical Trial Agreement to Study HORIZANT as a Potential Treatment for Alcohol Use Disorder 135
Jul 10, 2014: NICE recommends nalmefene treatment for alcohol dependence 136
Appendix 137
Methodology 137
Coverage 137
Secondary Research 137
Primary Research 137
Expert Panel Validation 137
Contact Us 137
Disclaimer 138
List of Tables
Number of Products under Development for Alcohol Addiction, H2 2016 11
Number of Products under Development for Alcohol Addiction - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2016 21
Alcohol Addiction - Pipeline by AbbVie Inc., H2 2016 22
Alcohol Addiction - Pipeline by Addex Therapeutics Ltd, H2 2016 23
Alcohol Addiction - Pipeline by Adial Pharmaceuticals, LLC, H2 2016 24
Alcohol Addiction - Pipeline by Astraea Therapeutics, LLC, H2 2016 25
Alcohol Addiction - Pipeline by AstraZeneca Plc, H2 2016 26
Alcohol Addiction - Pipeline by Bionex Pharmaceuticals LLC, H2 2016 27
Alcohol Addiction - Pipeline by Bioprojet SCR, H2 2016 28
Alcohol Addiction - Pipeline by Cerecor Inc., H2 2016 29
Alcohol Addiction - Pipeline by Curemark, LLC, H2 2016 30
Alcohol Addiction - Pipeline by Eli Lilly and Company, H2 2016 31
Alcohol Addiction - Pipeline by Ethypharm S.A., H2 2016 32
Alcohol Addiction - Pipeline by Euthymics Bioscience, Inc., H2 2016 33
Alcohol Addiction - Pipeline by H. Lundbeck A/S, H2 2016 34
Alcohol Addiction - Pipeline by Heptares Therapeutics Limited, H2 2016 35
Alcohol Addiction - Pipeline by Indivior Plc, H2 2016 36
Alcohol Addiction - Pipeline by Johnson & Johnson, H2 2016 37
Alcohol Addiction - Pipeline by Kinnov Therapeutics SAS, H2 2016 38
Alcohol Addiction - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 39
Alcohol Addiction - Pipeline by Lohocla Research Corporation, H2 2016 40
Alcohol Addiction - Pipeline by Omeros Corporation, H2 2016 41
Alcohol Addiction - Pipeline by Pfizer Inc., H2 2016 42
Alcohol Addiction - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 43
Alcohol Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016 44
Alcohol Addiction - Pipeline by VM Discovery, Inc., H2 2016 45
Alcohol Addiction - Pipeline by XenoPort, Inc., H2 2016 46
Alcohol Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016 47
Assessment by Monotherapy Products, H2 2016 48
Assessment by Combination Products, H2 2016 49
Number of Products by Stage and Target, H2 2016 51
Number of Products by Stage and Mechanism of Action, H2 2016 54
Number of Products by Stage and Route of Administration, H2 2016 57
Number of Products by Stage and Molecule Type, H2 2016 59
Alcohol Addiction - Dormant Projects, H2 2016 122
Alcohol Addiction - Dormant Projects (Contd..1), H2 2016 123
Alcohol Addiction - Dormant Projects (Contd..2), H2 2016 124
Alcohol Addiction - Discontinued Products, H2 2016 125
List of Figures
Number of Products under Development for Alcohol Addiction, H2 2016 11
Number of Products under Development for Alcohol Addiction - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Products, H2 2016 18
Assessment by Monotherapy Products, H2 2016 48
Assessment by Combination Products, H2 2016 49
Number of Products by Top 10 Targets, H2 2016 50
Number of Products by Stage and Top 10 Targets, H2 2016 50
Number of Products by Top 10 Mechanism of Actions, H2 2016 53
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 53
Number of Products by Routes of Administration, H2 2016 56
Number of Products by Stage and Routes of Administration, H2 2016 56
Number of Products by Molecule Types, H2 2016 58
Number of Products by Stage and Molecule Types, H2 2016 58
